abs290.txt	purpose		bevacizumab	is	a	vegf-specific	angiogenesis	inhibitor	indicated	as	anadjunct	to	chemotherapy	for	the	treatment	of	multiple	cancers		hypertension	iscommonly	observed	during	bevacizumab	treatment		and	high-grade	toxicity	can	limittherapy	or	lead	to	cardiovascular	complications		the	factors	that	contribute	tointerindividual	variability	in	blood	pressure	rise	during	bevacizumab	treatmentare	not	well	understood	experimental	design		to	identify	genomic	regionsassociated	with	bevacizumab-induced	hypertension	risk		sequencing	of	candidategenes	and	flanking	regulatory	regions	was	performed	on	61	patients	treated	withbevacizumab	(19	cases	developed	early-onset	grade	3	hypertension	and	42	controlshad	no	reported	hypertension	in	the	first	six	cycles	of	treatment)		snp-basedtests	for	common	variant	associations	and	gene-based	tests	for	rare	variantassociations	were	performed	in	174	candidate	genes	results		four	common	variantsin	independent	linkage	disequilibrium	blocks	between	slc29a1	and	hsp90ab1	wereamong	the	top	associations		validation	in	larger	bevacizumab-treated	cohortssupported	association	between	rs9381299	with	early	grade	3+	hypertension	(p	=0	01		or		2	4)	and	systolic	blood	pressure	>180	mm	hg	(p	=	0	02		or		2	1)	rs834576	was	associated	with	early	grade	3+	hypertension	in	calgb	40502	(p	=0	03		or		2	9)		these	snp	regions	are	enriched	for	regulatory	elements	that	maypotentially	increase	gene	expression		in	vitro	overexpression	of	slc29a1	in	humanendothelial	cells	disrupted	adenosine	signaling	and	reduced	nitric	oxide	levelsthat	were	further	lowered	upon	bevacizumab	exposure	conclusions		the	genomicregion	between	slc29a1	and	hsp90ab1	and	its	role	in	regulating	adenosinesignaling	are	key	targets	for	further	investigation	into	the	pathogenesis	ofbevacizumab-induced	hypertension		clin	cancer	res		24(19)		4734-44		Â©2018	aacr	
